{
    "clinical_study": {
        "@rank": "124294", 
        "arm_group": {
            "arm_group_label": "cultured Treg cells", 
            "arm_group_type": "Other", 
            "description": "co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant"
        }, 
        "brief_summary": {
            "textblock": "clinical trial of allospecific Tregs for prevention of acute GVHD in HLA identical sibling\n      transplants"
        }, 
        "brief_title": "Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-versus-host Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft Versus Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "to evaluate the safety of sirolimus based immune suppression and ex-vivo expanded donor\n      regulatory T cells for the prevention of acute graft-versus-host disease following\n      allogeneic hematopoietic cell transplantation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Diagnoses:\n\n             a. Hematologic malignancies - Acute myelogenous leukemia (AML), acute lymphoblastic\n             leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL),\n             non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM) - in\n             complete remission (CR) i. complete remission is defined per morphologic,\n             cytogenetic, FISH, molecular, and radiographic imaging studies appropriate for each\n             condition listed\n\n             1. AML, ALL\n\n          -  Normal values for absolute neutrophil count (>1000/microL) and platelet count\n             (>100,000/microL),\n\n          -  absence of extramedullary leukemia\n\n          -  Less than 5 percent blast cells present in the bone marrow 2. MDS\n\n          -  Bone marrow with \u22645 percent myeloblasts with normal maturation of all cell lines\n\n          -  Peripheral blood demonstrates hemoglobin \u226511 g/dL, platelets \u2265100 x 109/L,\n             neutrophils \u22651 x 109/L, and no circulating blasts 3. CLL\n\n          -  Absence of constitutional symptoms attributable to CLL\n\n          -  No lymph nodes >1.5 cm in diameter on computed tomography\n\n          -  No hepatomegaly or splenomegaly by computed tomography\n\n          -  Absolute neutrophil count >1500/microL\n\n          -  Platelet count >100,000/microL\n\n          -  No clonal lymphocytes in the peripheral blood by immunophenotyping\n\n          -  bone marrow with no evidence of clonal CLL (by flow cytometry and/or\n             immunohistochemistry 4. NHL\n\n          -  No clinical evidence of disease or disease-related symptoms\n\n          -  Typically FDG-avid lymphomas: a post-treatment residual mass of any size is permitted\n             as long as it is PET negative.\n\n          -  Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by CT.\n\n          -  Spleen and liver non-palpable and without nodules\n\n          -  If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be\n             negative; if morphologically indeterminate, immunohistochemistry should be negative\n             If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be\n             negative; if morphologically indeterminate, immunohistochemistry should be negative\n\n             5. HL\n\n          -  No clinical evidence of disease or disease-related symptoms\n\n          -  A post-treatment residual mass of any size is permitted as long as it is PET negative\n\n          -  Spleen and liver must be non-palpable and without nodules\n\n          -  If a pre-treatment bone marrow biopsy was positive, an adequate bone marrow biopsy\n             from the same site must be cleared of infiltrate; if this is indeterminate by\n             morphology, immunohistochemistry should be negative 6. MM\n\n          -  Absence of monoclonal protein in serum and urine by immunofixation with no current\n             evidence of soft tissue plasmacytoma\n\n          -  bone marrow aspirate and biopsy must demonstrate less than 5 percent clonal plasma\n             cells\n\n          -  In patients who lack measurable M proteins in the serum and urine being monitored\n             using the FLC levels, the definition of CR requires a normalization of the FLC ratio\n             in addition to the above criteria ii. MDS - may have achieved CR through either\n             hypomethylating agent therapy, induction chemotherapy, or other therapy iii. MDS -\n             low/intermediate-1 IPSS risk category patients are eligible only if they have failed\n             prior therapy or are transfusion-dependent\n\n          -  Peripheral blood WBC greater than 2,000 per microliter (required for collection of\n             dendritic cell precursors)\n\n          -  Adequate vital organ function:\n\n        LVEF \u2265 45% by MUGA scan FEV1, FVC, and DLCO \u2265 50% of predicted values on pulmonary\n        function tests Transaminases (AST, ALT) < 3 times upper limit of normal values Creatinine\n        clearance \u2265 50cc/min\n\n          -  Infectious disease criteria:\n\n             a. No active infection; infection controlled with antimicrobial therapy is not\n             excluded b. HIV negative by ELISA or RT-PCR [if ELISA is positive and RT-PCR is\n             negative, the ELISA is considered false positive] c. Hepatitis B and C negative by\n             serology or RT-PCR d. Must complete full screening panel: i. HIV 1, 2 serology and\n             RT-PCR ii. HTLV 1,2 serology iii. RPR serology iv. EBV serology v. CMV serology vi.\n             HSV serology vii.VZV serology\n\n          -  Performance status:  Karnofsky Performance Status Score \u2265 60%.\n\n          -  Agreement to utilize effective contraceptive methods during the study (for one year)\n\n        Exclusion Criteria:\n\n          -  Those with any Sorror's co-morbidity factors with score > 3\n\n          -  2 or more Sorror's factors with composite score of \u2265 3\n\n          -  Important modification to co-morbidity index calculation\n\n             a. DLCO will not be included in assessment of pulmonary risk, excepting those with\n             DLCO < 50%, who will merit a score of 3 and thereby be excluded from the trial.\n\n          -  Antithymocyte globulin (ATG) as part of the conditioning regimen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795573", 
            "org_study_id": "MCC-17263"
        }, 
        "intervention": {
            "arm_group_label": "cultured Treg cells", 
            "description": "co-culturing of recipient dendritic cells and donor Treg.  Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date)", 
            "intervention_name": "cultured Treg cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GVHD", 
            "AML", 
            "ALL", 
            "MDS", 
            "CLL", 
            "NHL", 
            "HL", 
            "MM"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "link": {
            "description": "H. LeeMoffitt Cancer Center & Research Institute", 
            "url": "http://www.moffitt.org/"
        }, 
        "location": {
            "contact": {
                "email": "joseph.pidala@moffitt.org", 
                "last_name": "Joseph Pidala, MD, MS", 
                "phone": "813-745-2556"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H Lee Moffitt Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Claudio Anasetti, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Melissa Alsina, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ernesto Ayala, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hugo Fernandez, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Teresa Field, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lia Perez, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jose Leonel Ochoa-Bayona, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Brian Betts, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fred Locke, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marcie Tomblyn, MD, MS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Taiga Nishihori, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mohamed Kharfan-Dabaja, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Janssen, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial of Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-versus-host Disease", 
        "overall_contact": {
            "email": "joseph.pidala@moffitt.org", 
            "last_name": "Joseph Pidala, MD, MS", 
            "phone": "813-745-2556"
        }, 
        "overall_official": {
            "affiliation": "Moffitt Cancer Center", 
            "last_name": "Joseph Pidala, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical evidence of acute GVHD will be recorded per standard grading scheme. GVHD grade will be reported weekly from day 0-100 both for site-specific involvement, as well as an overall composite score", 
            "measure": "acute GVHD incidence", 
            "safety_issue": "No", 
            "time_frame": "100 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}